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BACKGROUND
Variable Surgical Cath Significance
Current Age 26.7±10.5 30.9±10.5 p>.05, NS
Age at OR 19.9±10.1 26.8±11.5 p>.05, NS
Weight (kg) 66.2±25.5 69.4±20.6 p>.05, NS





DiGeorge Syndrome 13 5
Turner Syndrome 2 0
Other 7 7
Primary Cardiac Diagnosis p>.05, NS
Pulmonary Valve Stenosis 17 15
Tetralogy of Fallot 39 27
Pulmonary Atresia 16 11
Truncus Arteriosus 14 2
Left Sided Disease 17 7
Number of Surgical PV Interventions p>.05, NS
1 14 28
2 3 2







Indication for Intervention p>.05,NS
Pulmonary Stenosis 37 24
Pulmonary Regurgitation 45 23
Mixed Valve Disease 22 17
Table I
ACHD Cohorts
Variables Surgical Cath Significance
Hospital Length Of Stay 4 ; (2-30) 1 ; (1-3) P= .06
Pre-Stented N/A 73.40%
Type of Valve




Valve Size 23 ± 13 22 ± 12 p>.05, NS
Extubated in OR 54.50% 96.90% P<.0001
Bypass Time 132.3± 86.5 N/A
Reoperation Prior to 
Discharge 2 1 p>.05, NS
Readmitted Within 30 
Days 3 1 p>.05, NS
Death Within 30 Days 2 0 p>.05, NS
Major Surgical Complication P>.05, NS
Hemorrhage 1 2












Variables Surgical Cath Significance
Total Valves Placed 103 64
Interval Deaths 2 2
Valve Duration 1368 ± 1211 1256 ± 887 p>.05, NS
Valve Failures 12 3 p>.05, NS
Stenosis 6 1
Valve Break Down 5 1
Endocarditis 1 1
Valve In Place 89 59 p>.05, NS
Stenosis (≥Mod) 8 3
Regurgitation (≥Mod) 12 1
Table III
Valve Status
• Surgical PVR are highly successful with low mortality rates, low valve 
failures, and generally short hospital length of stay. Procedural 
complications are low and valve failure is rare. 
• Catheterization procedures are also highly successful and have a 
significantly shorter length of stay, have a higher extubated in the 
operating room rate, low mortality rate, and low valve failure.
• Endocarditis has been previously published as higher for catheterization 
PVRs but for this institution the endocarditis rate is low for both surgical 
and catheterization. 
• Catheterization pulmonary valve replacement is proven to be effective 
and should be used as the 1st recommendation for those that qualify for 
that type of intervention.
• 2018 AHA/ACC Guideline for the Management of Adults With Congenital 
Heart Disease: A Report of the American College of Cardiology/American 
Heart Association Task Force on Clinical Practice Guidelines. 
JAmCollCardiol2018;Aug 16
• Lee C, Park CS, Lee CH, et al. Durability of bioprosthetic valves in the 
pulmonary position: long-term follow-up of 181 implants in patients with 
congenital heart disease. J Thoracic Cardiovascular Surg. 
2011;142(2):351-358. doi:10.1016/j.jtcvs.2010.12.020
• Pulmonary valve repair and replacement. Mayo Clinic. March 17, 2020.
• To investigate pulmonary valve durability and outcomes in adults seen by the 
pediatric and adult congenital heart disease program at Children’s Hospital and 
Nebraska Medicine over since the advent of catheter based PVR.  
• Compare indications and medical comorbidities for patients that undergo a 
surgical pulmonary valve replacement to those that receive a catherization 
procedure. 
• Assess and compare pre- and post-operative statuses of the patients receiving 
pulmonary valve replacement 
• Congenital cardiac diseases involving the pulmonary valve are some of the 
most common forms of congenital heart disease. 
• Over 85% of patients with Congenital Heart Disease now live into adulthood 
making pulmonary valve replacement (PVR) one of the most common 
adulthood congenital procedures.
• Outcomes for PVR are well established but can differ by institution. Therefore, 
assessing our indications for replacement, valve outcomes, longevity, and data 
for our institution was important to compare to national averages.
• There are currently two methods for pulmonary valve replacement: 
• Surgical PVR has been the standard of care for the last several decades. 
Bioprosthetic valves are traditionally placed through an open sternotomy 
under cardiopulmonary bypass. Outcomes are generally excellent. Valves 
vary in structure and make-up, but generally last 10 or more years. 
• Catheter based pulmonary valves have been in existence since the mid 
2000s and within our program since early 2010s. Valves are placed under 
fluoroscopic guidance most commonly within a pre-existing surgically placed 
valve. Outcomes are generally excellent and have similar outcomes to 
surgical pulmonary valves.
• Catheter based PVR for native pulmonary valve disease will soon be available 
(Harmony) and establishing both surgical and catheter based pulmonary valve 
replacement will be important for future decision making. 
• IRB approval was achieved for this study
• Retrospective cross-sectional chart review
• Inclusion criteria: ACHD patients ≥18 years who underwent pulmonary valve 
replacement either through surgical or catheterization intervention in the last 
10 years.
• Patients were reviewed and described.
• Valve longevity, endocarditis, extubated in the operating room, reoperation, 
readmittance, and complications were assessed.
• Duration is calculated using the day of the valve replacement and the last 
known clinic date.
• Pulmonary stenosis, pulmonary regurgitation, and mixed valve disease are 
indicated using Echocardiograms and Cardiac MRI’s when present at the clinic 
date prior to the procedure and the most recent cardiac clinic date. 
